Topthema: Heuschnupfenzeit

Takeda Pharma Vertrieb GmbH & Co. KG

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...

European Academy of Allergy and Clinical Immunology

EAACI International Severe Asthma Forum (ISAF) Hybrid 2023: Advancing Severe Asthma Care

Zurich (ots/PRNewswire) - The Organising Committee of the EAACI International Severe Asthma Forum (ISAF) is pleased to announce the upcoming ISAF Hybrid 2023 event, scheduled to take place in the historic city of Rome from October 05 to October 07, 2023. This event will unite global experts and emerging professionals to address the challenges of severe asthma and ...

Takeda Pharma Vertrieb GmbH & Co. KG

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...

Grünenthal Group

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...

Lingoda GmbH

Lingoda Partners with Fēst Virtual Cooking to Offer Free Language and Cooking Classes for the Holidays / 2 in 1: Become a Master Chef and Improve your Language Skills

Almirall, S.A.

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials

Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...

DG-Nika AG

First pocket inhaler for Covid-19 and other viral mutations

Buochs (ots) - DG-Nika AG – a new approach to therapy & proactive protection from the pandemic The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-Nika AG research team has developed a solution for a new approach to protecting the ...

Boehringer Ingelheim

U.S. FDA Approves New Anti-HIV Drug Aptivus(R) for Use in Combination Therapy

Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...